Zobrazeno 1 - 10
of 39
pro vyhledávání: '"John R. Foster"'
Autor:
John R. Foster, Kharmen Billimoria, M. Estela del Castillo Busto, Stanislav Strekopytov, Heidi Goenaga‐Infante, Timothy J. Morley
Publikováno v:
Journal of Applied Toxicology. 42:1807-1821
Molybdenum is an essential dietary trace element required for several critical enzyme systems. High intake is associated with toxicity in ruminants and animal studies. The proposed therapeutic use of molybdenum-based drugs poses a potential risk for
Publikováno v:
Archives of toxicology. 95(3)
This review summarises the current state of knowledge regarding the physiology and control of production of thyroid hormones, the effects of chemicals in perturbing their synthesis and release that result in thyroid cancer. It does not consider the p
Publikováno v:
Toxicologic pathology. 48(3)
The increased concern on the consequence of exposure to multiple chemical combinations has led national regulatory authorities to develop different concepts to conduct risk assessments on chemical mixtures. Pesticide residues were identified as “pr
Autor:
John R. Foster, Anna Abrahamsson, Kevin J. Randall, Kathryn Pickup, Lars Weidolf, Kristin Samuelsson, Matt Jacobsen, Sunil Sarda, Ian D. Wilson
Publikováno v:
Xenobiotica. 44:186-195
1. The biotransformation, hepatic transporter and blood chemistry effects of troglitazone were investigated following 7 days of dosing at 600 mg/kg/day to chimeric murinized or humanized FRG mice, Mo-FRG and Hu-FRG mice, respectively. 2. Clinical che
Autor:
Paul G. Germann, Sabine Francke, Lindsay Tomlinson, Johannes Harleman, Gabriele Pohlmeyer-Esch, Charles E. Wood, Hirofumi Nagai, Agnes Schulte, Barbara Lenz, Henri Caplain, Takanori Harada, Xavier Palazzi, Mikala Skydsgaard, John E. Burkhardt, Wolfgang Kaufmann, Midori Yoshida, Sibylle Gröters, Kosei Inui, Vicki L. Dellarco, Pierluigi Fant, John R. Foster
Publikováno v:
Toxicologic pathology. 44(6)
The identification of adverse health effects has a central role in the development and risk/safety assessment of chemical entities and pharmaceuticals. There is currently a need for better alignment regarding how nonclinical adversity is determined a
Autor:
Robert R. Maronpot, Agnes Schulte, Karin Küttler, A. Nishikawa, Takanori Harada, Anthony P. Hall, Thomas Nolte, David E. Malarkey, John R. Foster, C. R. Elcombe, Wolfgang Kaufmann, Volker Strauss, Malcolm York, Anja Knippel
Publikováno v:
Toxicologic Pathology. 40:971-994
Preclinical toxicity studies have demonstrated that exposure of laboratory animals to liver enzyme inducers during preclinical safety assessment results in a signature of toxicological changes characterized by an increase in liver weight, hepatocellu
Autor:
Ian D. Wilson, Gerhard Gross, John R. Foster, Yoshio Morikawa, Timothy Schulz-Utermoehl, J. Gerry Kenna, Juuso Salmu, Matt Jacobsen, Sunil Sarda
Publikováno v:
Xenobiotica. 42:503-517
The pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone were investigated following daily oral dosing, at 300 and 600 mg/kg, for 7 days to control (SCID) and chimeric (PXB) mice with humanized livers. Clinical chemistr
Publikováno v:
Cell Biology and Toxicology. 27:267-284
The gastrointestinal (GI) tract is an important target organ for the toxicity of xenobiotics. The toxic effects of xenobiotics on this complex, heterogeneous structure have been difficult to model in vitro and have traditionally been assessed in vivo
Autor:
Alan R. Palmer, Deborah A. Hall, Ron Coxon, John R. Foster, Michael A. Akeroyd, John Chambers
Publikováno v:
Journal of the Acoustical Society of America
Functional magnetic resonance imaging (fMRI) is one of the principal neuroimaging techniques for studying human audition, but it generates an intense background sound which hinders listening performance and confounds measures of the auditory response
Autor:
Nigel Charles Barrass, Dominic Smethurst, D. Ross Camidge, Jim Growcott, John R. Foster, Helen Swaisland, Andrew Hughes, Salvatore Febbraro
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:391-398
AZD5438 is a novel cyclin-dependent kinase inhibitor with preclinical pharmacodynamic (PD) activity against a range of human tumour xenografts. A first-in-man tolerability and pharmacokinetic (PK) study involving single ascending doses of AZD5438 was